

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/13, 9/107	A 1	(11) International Publication Number: WO 97/22358 (43) International Publication Date: 26 June 1997 (26.06.97)
(21) International Application Number: PCT/CA96/00803 (22) International Filing Date: 3 December 1996 (03.12.96) (30) Priority Data: 280689 15 December 1995 (15.12.95) NZ (71)(72) Applicant and Inventor: SHERMAN, Bernard, Charles [CA/CA]; 150 Signet Drive, Weston, Ontario M9L 1T9 (CA).	(81) Designated States: AU, BR, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, IL, JP, KR, MX, NZ, RU, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	(54) Title: MICROEMULSION PRECONCENTRATES COMPRISING CYCLOSPORINS (57) Abstract A pharmaceutical composition in the form of a microemulsion concentrate comprising a cyclosporin dissolved in a solvent system further comprising a hydrophobic component, a hydrophilic component, and a surfactant, wherein either the hydrophobic component is selected from tocol, tocopherols, tocotrienols, and derivatives thereof, or the hydrophilic component is selected from propylene carbonate or polyethylene glycol having an average molecular weight of less than 1000.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

MICROEMULSION PRECONCENTRATES COMPRISING CYCLOSPORINS

TECHNICAL FIELD

5

The invention is directed to pharmaceutical compositions which facilitate the administration of cyclosporins.

BACKGROUND ART

10

The term "cyclosporins" as used herein shall mean the class of nonpolar polypeptides, as defined in the Merck Index, Eleventh Edition. One such cyclosporin is cyclosporin A, also known as "cyclosporine" and hereinafter referred to as "cyclosporine", known to be therapeutically active as an immunosuppressant.

15

The term "composition" as used herein is to be understood as meaning any composition containing a drug along with inactive ingredients that are pharmaceutically acceptable by reason of not being excessively toxic in the quantities required.

20

The term "solvent system" as used herein is to be understood to mean the material in which the drug (i.e. a cyclosporin) is dissolved. The solvent system may be a single solvent or a combination or mixture of ingredients included as solvents, surfactants, diluents or for other purposes.

25

Cyclosporins are hydrophobic and have low solubility in aqueous media. This makes it difficult to design pharmaceutical compositions which exhibit satisfactory absorption into systemic circulation after oral administration, or absorption into the target tissue upon topical administration.

30

- 2 -

The cyclosporin can be dissolved in an organic solvent (e.g. ethanol or propylene glycol), but if the solvent is water-miscible, when the composition is mixed with gastrointestinal fluid or other aqueous media, the cyclosporin will precipitate.

5

Various methods of overcoming this problem are known in the prior art, but all have certain limitations.

U.S. patent 4388307 discloses compositions comprising cyclosporine in an emulsion preconcentrate that is not water-miscible, but forms an emulsion upon being mixed into gastrointestinal fluids. A commercial product that has been sold under the trademark "Sandimmune" is made according to U.S. patent 4388307, and, more specifically, comprises cyclosporine dissolved in a solvent system comprising ethanol, a vegetable oil and a surfactant. Although this composition was superior to previously known compositions, it still exhibits absorption that is less than the maximum possible and is variable. Also, the use of ethanol has disadvantages, as ethanol is volatile, and the capsules of Sandimmune must be individually packaged in metallic pouches to avoid loss of ethanol by evaporation.

15

U.S. patent 5342625 discloses compositions that are said to be superior in certain respects to the compositions of U.S. patent 4388307. The compositions of U.S. patent 5342625 comprise, in addition to the cyclosporin, a hydrophilic phase, a lipophilic (i.e. hydrophobic) phase and a surfactant. The hydrophilic phase is either propylene glycol or a pharmaceutically acceptable alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkanediol.

20

25

The lipophilic phase comprises a solvent which is non-miscible with the hydrophilic phase, and is preferably a fatty acid triglyceride.

- 3 -

It is disclosed that compositions according to U.S. patent 5342625, when added to water, disperse into emulsions with droplet size of less than 2000Å, which is smaller than obtained with prior art compositions, thus leading to improved absorption.

5

Emulsions with droplet size of less than 2000Å are defined as "microemulsions". Compositions that, upon addition to water, disperse into microemulsions are called "microemulsion preconcentrates".

10

A composition made according to the disclosure of U.S. patent 5342625 is now marketed under the trademark "Neoral", in the form of both a soft gelatin capsule which encloses the microemulsion preconcentrate and an oral liquid which is a microemulsion preconcentrate intended to be diluted into an aqueous drink before ingestion.

15

For both the soft gelatin capsules and the oral liquid, the labelling indicates that the "Neoral" emulsion preconcentrate comprises cyclosporine dissolved in ethanol and propylene glycol as hydrophilic solvents, corn oil as lipophilic (hydrophobic) solvent, and polyoxyl 40 hydrogenated castor oil as surfactant. It also contains dl-alpha-tocopherol at a level of about one percent by weight as antioxidant, apparently to prevent oxidation of the corn oil.

20

While "Neoral" does enable improved absorption relative to Sandimmune, it still has certain undesirable properties. Specifically:

25

1. Ethanol is volatile, so that the soft gelatin capsules have to be packaged individually in metallic pouches to prevent evaporation of the ethanol.

- 4 -

2. The melting point of the microemulsion concentrate is about 20°C so that it may solidify at room temperature. This means that the oral solution may have to be warmed and melted to be dispensed. Also it cannot be mixed with a cold aqueous drink and is limited to being mixed into warm aqueous drinks.
3. Ethanol contributes to an undesirable taste of the microemulsion concentrate, so that, even after dilution into a sweetened drink, there is still a somewhat unpleasant taste.
4. The concentration of cyclosporine is limited to about 100 mg per mL so that a soft gelatin capsules containing 100 mg of cyclosporine is larger than desirable and difficult to swallow.
- International Publication Number W094/25068 discloses improved compositions in the form of microemulsion concentrates in which the principal solvent for the cyclosporin is an alcohol which is selected from alcohols having a boiling point above 100°C and a solubility in water of under 10 g per 100 g at 20°C. Such alcohols are referred to as a hydrophobic alcohols.
- It is disclosed that a hydrophobic alcohol can be used in place of the combination of hydrophilic and hydrophobic solvents.
- Preferred hydrophobic alcohols, within the scope of the disclosure of W094/25068, are saturated alkyl alcohols having 8 to 14 carbon atoms per molecule, including 1-octyl, 2-octyl, 1-decyl, 1-dodecyl and 1-tetradecyl alcohols.

- 5 -

Compositions according to the disclosure of W094/25068 overcome some of the problems of prior art compositions. However, the hydrophobic alcohols have a foul taste so that, even after dilution into a sweetened aqueous drink, there is still an unpleasant taste.

5

In view of the difficulties with prior art compositions, the object of the invention is to enable microemulsion preconcentrates comprising cyclosporins which use combinations of excipients (i.e. inactive ingredients) not disclosed in the prior art, and thereby overcome some or all of the problems encountered with prior art compositions.

10

SUMMARY OF THE INVENTION

As with compositions of U.S. patent 5342625, compositions of the within invention take the form of microemulsion preconcentrates comprising a cyclosporin dissolved in a solvent system further comprising at least one hydrophobic solvent, at least one hydrophilic solvent and at least one surfactant.

15

For purposes of the present disclosure and claims, the term "hydrophobic" will be taken as meaning being insoluble in water or substantially insoluble in water, i.e. having a solubility of less than 1 part per 1000 parts of water by weight at 20°C, and the term "hydrophilic" will be taken as meaning miscible with water or having a solubility of more than 1 part per 100 parts of water by weight at 20°C.

20

One feature of the present invention is to use, as hydrophobic solvent, an ingredient selected from tocol, tocopherols, tocotrienols, and derivatives thereof.

25

- 6 -

Another feature of the within invention is to use, as hydrophilic solvent, solvents other than those disclosed in U.S. Patent No. 5,342,625 and in particular a solvent selected from propylene carbonate and polyethylene glycols having average molecular weight of less than 1000.

5

More particularly the invention is a pharmaceutical composition in the form of a microemulsion preconcentrate comprising a cyclosporin dissolved in a solvent system further comprising a hydrophobic component, a hydrophilic component and a surfactant, wherein either:

10

1) the hydrophobic component is selected from tocol, tocopherols and tocotrienols, and derivatives thereof, and comprises at least about two percent of the composition by weight, or

15

2) the hydrophilic component is propylene carbonate or polyethylene glycol having average molecular weight of less than 1000.

DETAILED DESCRIPTION OF THE INVENTION

20

A microemulsion preconcentrate comprising a cyclosporin must contain a hydrophobic solvent and surfactant.

25

A hydrophobic solvent is needed, because if the cyclosporin is dissolved in only a hydrophilic solvent, then when the composition is mixed with a aqueous medium, the hydrophilic solvent will dissolve in the water, causing precipitation of the cyclosporin.

- 7 -

It is also necessary that the solvents used in the composition have adequate capacity to dissolve the cyclosporin and to keep it dissolved without precipitation.

5 As aforesaid, International Patent Number WO94/25068 discloses use of hydrophobic alcohols as solvents, and such alcohols, being both hydrophobic and having adequate solvent capacity for cyclosporins, can render it unnecessary to use a hydrophilic solvent as cosolvent. However, when the hydrophobic solvent is not an alcohol, it appears to be necessary to use as cosolvent a hydrophilic solvent that is a good solvent for the cyclosporins.

10

In U.S. patent 5342625, the only hydrophobic solvents that are disclosed are fatty acid triglycerides, and it is stated that especially suitable are neutral oils, e.g. neutral plant oils.

15

As aforesaid, one feature of the within invention is to use, as hydrophobic solvent, an ingredient selected from tocol, tocopherols and tocotrienols, and derivatives thereof.

20

The term "tocopherols" as used herein is to be understood to mean any one of or a mixture of any of the compounds which can be regarded as a substituted tocol and is identified as a type of tocopherol in the Merck Index Eleventh Edition at entry numbers 9417 to 9423 inclusive and entry number 9832, specifically including alpha-, beta-, delta- and gamma-tocopherol.

25

Alpha-tocopherol is also known as Vitamin E.

- 8 -

The term "tocotrienol" as used herein shall be understood to mean any one of or a mixture of alpha-, beta-, delta- and gamma-tocotrienol. Tocotrienols are similar to tocopherols but have an unsaturated side chain consisting of three double bonds.

5 The term "derivative" will be understood to mean any compound that can be formed by a reaction with any compound selected from tocol, tocopherols and tocotrienols. Derivatives will thus include, for example, tocol acetate, and alpha-tocopherol acetate.

10 Some or all of tocol, the tocopherols and the tocotrienols, and derivatives thereof are available as different stereoisomers, and it will be understood that the different stereoisomer or mixtures thereof are included within the definition.

15 Preferred as hydrophobic solvents are alpha-tocopherol, alpha-tocopherol acetate, and natural mixed tocopherols.

Especially preferred is natural mixed tocopherols. These are available, for example, as products sold under the tradenames Tenox GT-2 by Eastman Chemical Products Inc. and Coviox T70 by Henkel Corporation.

20 Tenox GT-2 and Coviox T70 both are comprised of about 70% total tocopherols and 30% vegetable oil. The total tocopherol content in these products is made up of approximately 12% to 14% d-alpha, 62% to 65% d-gamma, 23% to 24% d-delta and 1% d-beta.

25 The minimum effective amount of the hydrophobic solvent selected from tocol, tocopherols and tocotrienols, and derivatives thereof is about two per cent of the total composition by weight. The amount will preferably be at least four percent

- 9 -

of the composition by weight, and most preferably from about eight percent to about twenty-five percent.

As aforesaid, a second feature of the present invention is to use, as
5 hydrophilic solvent, solvents other than those disclosed in U.S. patent 5342625, and in particular, a solvent selected from propylene carbonate and polyethylene glycols having average molecular weight of less than 1000.

The hydrophilic solvents used in the prior art have exhibited several
10 problems including the following:

1. They may be excessively volatile so that a capsule containing the composition must be packed in metallic foil to prevent evaporation.
- 15 2. They may exhibit foul taste.
3. They may be excessively hydrophilic so that when the composition is mixed with water they tend to be extracted from the composition causing some precipitation of the cyclosporin.
- 20 4. The melting points of compositions using such solvents may not be low enough to enable the compositions to be dispersed in cold aqueous drinks.

It has been found that some or all of these problems can be overcome by
25 selecting a hydrophilic solvent from among propylene carbonate and polyethylene glycols having an average molecular weight of less than 1000. Particularly preferred are propylene carbonate and polyethylene glycols having average molecular weight from about 200 to about 400. Most preferred is propylene carbonate.

- 10 -

While the two features of the invention may be used independently of each other, it is especially preferred to use them together. Especially preferred compositions are thus compositions which comprise both a hydrophobic solvent selected from tocol, tocopherols and tocotrienols, and derivatives thereof and a hydrophilic solvent selected from propylene carbonate and polyethylene glycols having an average molecular weight of less than 1000.

Compositions of the within invention will comprise, in addition to the cyclosporin, a hydrophobic solvent, and a hydrophilic solvent, at least one surfactant.

Examples of suitable surfactants are:

- i) Reaction products of natural or hydrogenated vegetable oils and ethylene glycol; i.e., polyoxyethylene glycolated natural or hydrogenated vegetable oils; for example polyoxyethylene glycolated natural or hydrogenated castor oils. Particularly suitable are the products designated in the United States Pharmacopoeia and National Formulary as Polyoxyl 35 Castor Oil and Polyoxyl 40 Hydrogenated Castor Oil, which are available under the trade names Cremophor EL and Cremophor RH40 respectively. Also suitable for use in this category are the various tensides available under the trade names Nikkol, e.g. Nikkol HCO-60. Nikkol HCO-60 is a reaction product of hydrogenated castor oil and ethylene oxide.
- ii) Polyoxyethylene-sorbitan-fatty acid esters; e.g. mono- and tri-lauryl, palmityl, stearyl and oleyl esters; e.g. products of the type known as polysorbates and commercially available under the trade name "Tween".

- 11 -

- iii) Polyoxyethylene fatty acid esters; for example, polyoxyethylene stearic acid esters of the type known and commercially available under the trade name Myrj as well as polyoxyethylene fatty acid esters known and commercially available under the trade name "Cetiol HE".
- 5
- iv) Polyoxyethylene-polyoxypropylene co-polymers, e.g. of the type known and commercially available under the trade names "Pluronic" and "Emkalyx".
- v) Polyoxyethylene-polyoxypropylene block co-polymers, e.g. of the type known and commercially available under the trade name "Poloxamer".
- 10
- vi) Dioctylsuccinate, dioctylsodiumsulfosuccinate, di-[2-ethylhexyl]-succinate or sodium lauryl sulfate.
- vii) Phospholipids, in particular lecithins.
- 15
- viii) Propylene glycol mono- and di-fatty acid esters such as propylene glycol dicaprylate, propylene glycol dilaurate, propylene glycol hydroxystearate, propylene glycol isostearate, propylene glycol laurate, propylene glycol ricinoleate, propylene glycol stearate and so forth.
- 20
- ix) Bile salts; e.g. alkali metal salts, for example sodium taurocholate.
- x) Trans-esterification products of natural vegetable oil triglycerides and polyalkylene polyols; e.g. of the type known and commercially available under the trade name Labrafil M1944CS.
- 25

- 12 -

- xi) Mono-, di- and mono/di-glycerides, especially esterification products of caprylic or capric acid with glycerol.
 - xii) Sorbitan fatty acid esters: for example, of the type known and commercially available under the trade name Span.
 - xiii) Pentaerythritol fatty acid esters and polyalkylene glycol ethers: for example pentaerythrite-dioleate, -distearate, -monolaurate, -polyglycol ether and -monostearate as well as pentaerythrite-fatty acid esters.
 - xiv) Monoglycerides; e.g. glycerol monooleate, glycerol monopalmitate and glycerol monostearate; for example as known and commercially available under the trade names Myvatex, Myvaplex and Myverol, and acetylated, e.g. mono- and di-acetylated mono-glycerides; for example as known and commercially available under the trade name Myvacet.
 - xv) Glycerol triacetate or (1, 2, 3)-triacetin; and
 - xvi) Sterols and derivatives thereof, for example cholesterol and derivatives thereof, in particular phytosterols; e.g. products comprising sitosterol, campesterol or stigmasterol, and ethylene oxide adducts thereof, for examples soya sterols and derivatives thereof, such as known under the trade name Generol.
- Suitable surfactants will not necessarily be limited to those listed above, but will be understood to include any compound which causes the composition to be more easily dispersible in water.

- 13 -

Preferred surfactants are reaction products of natural or hydrogenated vegetable oils and ethylene glycol: i.e., polyoxyethylene glycolated natural or hydrogenated vegetable oils.

5 Especially preferred surfactants are polyoxyethylene glycolated natural or hydrogenated castor oils, including those designated in the United States Pharmacopoeia and National Formulary as Polyoxyl 35 Castor Oil and Polyoxyl 40 Hydrogenated Castor Oil.

10 It will be understood that not all surfactants will act equally well with all solvents to improve dispersion in water. Determination of suitable combinations of hydrophobic solvent, hydrophilic solvent, and surfactant for particular applications within the scope of the invention will be within the capability of persons skilled in the art of product formulation.

15 Compositions in accordance with the invention may contain other ingredients in addition to the drug, one or more hydrophobic solvents, one or more hydrophilic solvents and one or more surfactants.

20 For example, the composition may include, in addition to the foregoing, one or more other ingredients that are included as diluents.

 A composition in accordance with the invention may also contain, for example, a thickening agent (i.e. viscosity increasing agent). Suitable thickening
25 agents may be any of those known and employed in art, including, for example, pharmaceutically acceptable polymeric materials and inorganic thickening agents. However, where oral administration is intended, the use of thickening agents as

- 14 -

aforesaid will generally not be required. Use of thickening agents is, on the other hand, indicated, e.g. where topical application is foreseen.

5 Compositions in accordance with the invention may also include one or more further ingredients: such as anti-oxidants, flavouring agents and so forth.

10 Compositions in accordance with the invention may be liquids at ambient temperature or they may be solids prepared, for example, by use of a hydrophobic solvent or surfactant with melting point above ambient temperature. The ingredients may be blended at a temperature above the melting point and then used to fill capsules while still molten, or cooled to form solids. The solids may be ground into granules or powder for further processing; for example, filling capsules or manufacture of tablets.

15 If it is desired to increase the melting point to ensure that the composition is a solid at room temperature, this may be accomplished by adding a further ingredient with a relatively high melting point, such as, for example, polyethylene glycol with average molecular weight of above 1000.

20 Capsules or tablets may be further processed by applying coatings thereto.

Especially where oral administration is contemplated, compositions in accordance with the invention may comprise end dosage forms for administration as microemulsion preconcentrates. For example the microemulsion preconcentrate
25 may be directly used as liquid for oral ingestion, parenteral use, or topical application or it may be encapsulated into gelatin capsules for oral ingestion.

- 15 -

However, the present invention also provides pharmaceutical compositions in which the microemulsion preconcentrate is further processed into a microemulsion. Thus where oral administration is practised, microemulsions obtained, e.g. by diluting a microemulsion preconcentrate with water or other aqueous medium (for example, a sweetened or flavoured preparation for drinking), may be employed as formulations for drinking. Similarly, where topical application is foreseen, compositions comprising a microemulsion preconcentrate, a thickening agent, and water will provide an aqueous microemulsion in gel, paste, cream or like form.

10

Compositions in accordance with the present invention, whether microemulsion preconcentrates or microemulsions, may be employed for administration in any appropriate manner and form; e.g. orally, as liquids or granules or in unit dosage form, for example in hard or soft gelatin encapsulated form, parenterally or topically; e.g. for application to the skin; for example in the form of a cream, paste, lotion, gel, ointment, poultice, cataplasm, plaster, dermal patch, powder, topically applicable spray, or the like, or for ophthalmic application; for example in the form of an eye-drop, lotion or gel formulation. Readily flowable forms may also be employed; e.g. for intralesional injection for the treatment of psoriasis, or may be administered rectally. Compositions in accordance with the invention are, however, primarily intended for oral or topical application, including application to the skin or eyes.

15
20

The relative proportion of the cyclosporin and other ingredients in the compositions of the invention will, of course, vary considerably depending on the particular type of composition concerned; e.g. whether it is a microemulsion preconcentrate or microemulsion, the route of administration, and so forth. The relative proportions will also vary depending on the particular ingredients employed

25

- 16 -

and the desired physical characteristics of the composition, e.g. in the case of a composition for topical use, whether this is to be a free flowing liquid or a paste. Determination of workable proportions in any particular instance will generally be within the capability of persons skilled in the art. All indicated proportions
5 described herein are accordingly to be understood as being examples and not as not limiting the invention in its broadest aspect.

Compositions for topical use suitably comprise one or more carriers or diluents and/or other ingredients (e.g. thickening agents, emulsifying agents,
10 preserving agents, moisturizing agents, colourants and so forth) providing a suitable carrier.

Selection of excipients for the preparation of such formulations will, of course, be determined by the type of formulation desired as well as the particular
15 condition to be treated, the area to be treated, and the effect desired. Some conditions will more suitably be treated with hydrophobic, e.g. fat-based compositions, for example compositions in accordance with the invention comprising a petrolatum based ointment or cream as carrier medium. In contrast, compositions for use in the treatment of some conditions will more appropriately be
20 treated with more hydrophilic compositions.

By use of suitable individual carrier ingredients or mixtures thereof, compositions may be obtained in liquid or semi-solid form.

25 The invention will be more fully understood by the following examples which are illustrative but not limiting of compositions in accordance with the present invention.

- 17 -

EXAMPLES

5 In each of the following examples the ingredients by weight were placed in a container in the proportions shown, after the polyoxyl 40 hydrogenated castor oil was liquified by warming it to above 30°C.

Example 1

10	cyclosporine	1.0
	ethanol	0.8
	dl-alpha-tocopherol acetate	1.2
	polyoxyl 40 hydrogenated castor oil	<u>7.0</u>
		10.0

15

Example 2

	cyclosporine	1.0
	benzyl alcohol	0.5
20	polyethylene glycol 300	2.0
	dl-alpha-tocopheryl acetate	1.0
	polyoxyl 40 hydrogenated castor oil	<u>5.5</u>
		10.0

25

Example 3

	cyclosporine	1.0
	ethanol	0.8

- 18 -

dl-alpha-tocopherol	1.2
polyoxyl 40 hydrogenated castor oil	<u>7.0</u>
	10.0

5 Example 4

	cyclosporine	1.0
	propylene carbonate	2.5
	dl-alpha-tocopherol	1.5
10	polyoxyl 40 hydrogenated castor oil	<u>5.0</u>
		10.0

15

Example 5

	cyclosporine	1.0
	propylene carbonate	2.0
20	dl-alpha-tocopherol	2.0
	polyoxyl 40 hydrogenated castor oil	<u>5.0</u>
		10.0

Example 6

25

	cyclosporine	1.0
	propylene carbonate	3.0
	Coviox T70	1.5

- 19 -

polyoxyl 40 hydrogenated castor oil	<u>5.4</u>
	10.9

5 In the case of all of examples 1 to 6, upon blending and heating a clear liquid was formed.

 In the case of each of examples 1 to 6, when a quantity of the composition was added to water and upon shaking, the composition dispersed to form a
10 microemulsion.

 The composition of each of examples 1 to 6 is a microemulsion concentrate directly useable as drops for oral ingestion or as a liquid for
 ophthalmic or topical use. Alternatively, these compositions may be further
15 processed in various ways previously described, including, for example, their incorporation into gelatin capsules or tablets for oral ingestion, or into microemulsions and various other forms for oral or topical use.

 For example, they may be mixed into water or other aqueous media and used
20 as a drink. Alternatively, they may be incorporated into a cream, ointment, gel or the like by combination with further additives, e.g., thickening agents, paraffins, etc. as hereinbefore described.

 In the case of each of examples 4, 5 and 6, the melting point of the
25 composition is well below 20°C, so that these compositions are especially well suited for use as concentrates to be added to an aqueous medium and used as a drink, regardless of whether the drink is warm or cold.

- 20 -

INDUSTRIAL APPLICABILITY

From the foregoing description it will be apparent that in the present invention there is provided an improved pharmaceutical composition which permits
5 the more efficient administration and absorption of cyclosporins.

- 21 -

WHAT IS CLAIMED:

1. A pharmaceutical composition in the form of a microemulsion
preconcentrate comprising a cyclosporin dissolved in a solvent system further
5 comprising a hydrophobic component, a hydrophilic component and a surfactant,
wherein either:
 - 1) the hydrophobic component is selected from tocol, tocopherols and
tocotrienols, and derivatives thereof, and comprises at least about two
10 percent of the composition by weight, or
 - 2) the hydrophilic component is propylene carbonate or polyethylene
glycol having average molecular weight of less than 1000.
- 15 2. A pharmaceutical composition in the form of a microemulsion
preconcentrate comprising a cyclosporin dissolved in a solvent system further
comprising a hydrophobic component, a hydrophobic component and a surfactant,
wherein the hydrophobic component is selected from tocol, tocopherols and
tocotrienols, and derivatives thereof, and comprises at least four per cent of the
20 composition by weight.
3. A composition according to claim 2 wherein the hydrophobic component
comprises at least eight per cent of the composition by weight.
- 25 4. A composition according to any one of claims 1 to 3 wherein the
hydrophobic component is selected from tocopherols and derivatives thereof.

- 22 -

5. A composition according to claim 4 wherein the hydrophobic component is vitamin E or vitamin E acetate.
6. A composition according to claim 4 wherein the hydrophobic composition is natural mixed tocopherols.
7. A composition according to any one of claims 1 to 6 wherein the hydrophilic component is propylene carbonate or polyethylene glycol having average molecular weight of not more than about 600.
8. A composition according to any one of claims 1 to 7 wherein the hydrophilic component is propylene carbonate.
9. A pharmaceutical composition in the form of a microemulsion preconcentrate comprising a cyclosporin dissolved in a solvent system further comprising a hydrophobic component, a hydrophilic component and a surfactant, wherein the hydrophilic component is propylene carbonate or polyethylene glycol having average molecular weight less than 1000.
10. A composition as in claim 9 wherein the hydrophilic component is propylene carbonate.
11. A pharmaceutical composition in the form of a microemulsion preconcentrate comprising a cyclosporin dissolved in a solvent system wherein said solvent system further comprises a hydrophobic component selected from tocol, tocopherols, tocotrienols, and derivatives thereof; a hydrophilic component selected from propylene carbonate and polyethylene glycols having average molecular

- 23 -

weight of less than 1000; and a surfactant, and wherein said hydrophobic component comprises at least about two per cent of the composition by weight.

12. A composition according to any one of claims 1 to 11 wherein the
5 cyclosporin is cyclosporine.

13. A composition according to any one of claims 1 to 12 wherein the surfactant comprises a polyoxyethylene glycolated natural or hydrogenated vegetable oil.

10 14. A composition as in any one of claims 1 to 13 adapted for oral administration.

15. A composition according to any one of claims 1 to 14 comprising from about 5% to about 20% by weight of cyclosporin.

15

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 96/00803

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	WO 96 36316 A (ABBOTT) 21 November 1996 see the whole document ---	1-15
Y,P	WO 96 13273 A (SANDOZ) 9 May 1996 see the whole document ---	1-15
Y,P	EP 0 712 631 A (BIOGAL) 22 May 1996 see the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 96/00803

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 589843 A	30-03-94	CA 2106827 A	26-03-94
		DE 4332436 A	31-03-94
		FR 2696094 A	01-04-94
		GB 2270842 A,B	30-03-94
		JP 6199683 A	19-07-94

US 5342625 A	30-08-94	AU 627220 B	20-08-92
		AU 4140089 A	22-03-90
		BE 1003105 A	26-11-91
		BG 60525 B	28-07-95
		CA 1332150 A	27-09-94
		CH 679118 A	31-12-91
		CY 1711 A	06-05-94
		DE 3930928 A	22-03-90
		DK 171433 B	28-10-96
		FI 98046 B	31-12-96
		FR 2636534 A	23-03-90
		GB 2222770 A,B	21-03-90
		GR 1000456 B	30-07-92
		HK 86593 A	27-08-93
		HU 9500318 A	30-10-95
		IE 60764 B	10-08-94
		IL 91642 A	12-04-94
		JP 2121929 A	09-05-90
		JP 7025690 B	22-03-95
		LU 87586 A	07-05-91
		NL 8902315 A	17-04-90
		NO 180362 B	30-12-96
		PT 91731 B	09-08-95
		SE 8903042 A	11-05-90

FR 2636534 A	23-03-90	AU 627220 B	20-08-92
		AU 4140089 A	22-03-90
		BE 1003105 A	26-11-91
		BG 60525 B	28-07-95
		CA 1332150 A	27-09-94
		CH 679118 A	31-12-91
		CY 1711 A	06-05-94
		DE 3930928 A	22-03-90
		DK 171433 B	28-10-96

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 96/00803

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2636534 A		FI 98046 B	31-12-96
		GB 2222770 A,8	21-03-90
		GR 1000456 B	30-07-92
		HK 86593 A	27-08-93
		HU 9500318 A	30-10-95
		IE 60764 B	10-08-94
		IL 91642 A	12-04-94
		JP 2121929 A	09-05-90
		JP 7025690 B	22-03-95
		LU 87586 A	07-05-91
		NL 8902315 A	17-04-90
		NO 180362 B	30-12-96
		PT 91731 B	09-08-95
		SE 8903042 A	11-05-90
		US 5342625 A	30-08-94
GB 2282586 A	12-04-95	AU 7423794 A	13-04-95
		CA 2132933 A	29-03-95
		CN 1108930 A	27-09-95
		CZ 9402360 A	12-04-95
		EP 0649651 A	26-04-95
		FI 944452 A	29-03-95
		FR 2710532 A	07-04-95
		HU 70417 A	30-10-95
		IT RM940613 A	28-03-95
		JP 7149625 A	13-06-95
		NO 943563 A	29-03-95
		NZ 264536 A	25-09-96
		PL 305188 A	03-04-95
		SK 115794 A	10-05-95
		ZA 9407567 A	28-06-96
WO 9511039 A	27-04-95	EP 0724452 A	07-08-96
WO 9636316 A	21-11-96	NONE	
WO 9613273 A	09-05-96	AU 3924895 A	23-05-96
EP 712631 A	22-05-96	CZ 9501054 A	17-07-96
		DE 19543271 A	05-06-96

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 96/00803

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 712631 A		GB 2295546 A	05-06-96
		PL 311430 A	27-05-96
		SI 9500350 A	30-06-96
		SK 54495 A	05-02-97
		US 5583105 A	10-12-96

INTERNATIONAL SEARCH REPORT

Int. l. Application No.
PCT/CA 96/00803

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/13 A61K9/107

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 589 843 A (SANDOZ) 30 March 1994 see the whole document ---	1-15
Y	US 5 342 625 A (B. HAUSER ET AL.) 30 August 1994 cited in the application see the whole document ---	1-15
Y	FR 2 636 534 A (SANDOZ) 23 March 1990 see the whole document ---	1-15
Y	GB 2 282 586 A (SCHERER) 12 April 1995 see the whole document ---	1-15
Y	WO 95 11039 A (HEXAL PHARMA) 27 April 1995 see the whole document ---	1-15
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 April 1997

Date of mailing of the international search report

24.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Scarponi, U